CR20220618A - Nuevas proteinas de unión a repeticiones de anquirina y sus usos - Google Patents

Nuevas proteinas de unión a repeticiones de anquirina y sus usos

Info

Publication number
CR20220618A
CR20220618A CR20220618A CR20220618A CR20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A CR 20220618 A CR20220618 A CR 20220618A
Authority
CR
Costa Rica
Prior art keywords
proteins
ankyrin repeat
new
binding proteins
nucleic acids
Prior art date
Application number
CR20220618A
Other languages
English (en)
Inventor
Patrick Amstutz
Valerie Perrine Calabro
Marcel Walser
Original Assignee
Molecular Partners Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners Ag filed Critical Molecular Partners Ag
Publication of CR20220618A publication Critical patent/CR20220618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a proteínas de unión recombinantes que comprenden uno o más dominios de repetición de anquirina diseñados con especificidad de unión para proteínas de espiga de coronavirus, ácidos nucleicos que codifican dichas proteínas, composiciones farmacéuticas que comprenden dichas proteínas o ácidos nucleicos, y el uso de dichas proteínas, ácidos nucleicos o composiciones farmacéuticas en el tratamiento de enfermedades por coronavirus, particularmente enfermedades causadas por el SARS–CoV–2.
CR20220618A 2020-05-06 2021-05-06 Nuevas proteinas de unión a repeticiones de anquirina y sus usos CR20220618A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063020882P 2020-05-06 2020-05-06
US202063021024P 2020-05-06 2020-05-06
US202063057477P 2020-07-28 2020-07-28
US202063069174P 2020-08-24 2020-08-24
US202163145192P 2021-02-03 2021-02-03
PCT/IB2021/000320 WO2021224686A1 (en) 2020-05-06 2021-05-06 Novel ankyrin repeat binding proteins and their uses

Publications (1)

Publication Number Publication Date
CR20220618A true CR20220618A (es) 2023-01-19

Family

ID=78412258

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220618A CR20220618A (es) 2020-05-06 2021-05-06 Nuevas proteinas de unión a repeticiones de anquirina y sus usos

Country Status (16)

Country Link
US (2) US11466062B2 (es)
EP (1) EP4146691A1 (es)
JP (1) JP2023525518A (es)
KR (1) KR20230006558A (es)
CN (1) CN115916815A (es)
AU (1) AU2021267411A1 (es)
BR (1) BR112022022456A2 (es)
CA (1) CA3176845A1 (es)
CL (1) CL2022003044A1 (es)
CO (1) CO2022016595A2 (es)
CR (1) CR20220618A (es)
IL (1) IL297940A (es)
MX (1) MX2022013945A (es)
PE (1) PE20231074A1 (es)
TW (1) TW202208404A (es)
WO (1) WO2021224686A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
JP2023525518A (ja) * 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US11981710B2 (en) 2020-08-18 2024-05-14 Athebio Ag N-terminal capping modules of ankyrin repeat domains
EP3957649A1 (en) * 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
TWI796597B (zh) * 2020-09-21 2023-03-21 長庚大學 使用紫蘇之經水萃取的產物來對抗冠狀病毒感染的方法
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
WO2022150636A1 (en) * 2021-01-07 2022-07-14 The Board Of Regents Of The University Of Texas System Engineered stable ace2 protein variants as antiviral nebulized therapeutics
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
US20230104171A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Engineered Alum-binding SARS-CoV-2 Immunogens
EP4475869A4 (en) * 2022-02-11 2026-04-29 Texas A & M Univ Sys SARS-CoV-2 NEUTRALIZING SYNTHETIC PROTEINS
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2014001442A1 (en) * 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
WO2020245746A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
JP7611173B2 (ja) 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
JP2023525518A (ja) * 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途

Also Published As

Publication number Publication date
US20210347835A1 (en) 2021-11-11
TW202208404A (zh) 2022-03-01
PE20231074A1 (es) 2023-07-17
EP4146691A1 (en) 2023-03-15
AU2021267411A1 (en) 2022-12-08
CA3176845A1 (en) 2021-11-11
CL2022003044A1 (es) 2023-06-02
CN115916815A (zh) 2023-04-04
US11466062B2 (en) 2022-10-11
BR112022022456A2 (pt) 2023-01-10
JP2023525518A (ja) 2023-06-16
MX2022013945A (es) 2023-02-14
WO2021224686A1 (en) 2021-11-11
US20220235103A1 (en) 2022-07-28
CO2022016595A2 (es) 2022-12-09
KR20230006558A (ko) 2023-01-10
IL297940A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
CO2022016595A2 (es) Nuevas proteinas de unión a repeticiones de anquirina y sus usos
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
BR112022011177A2 (pt) Domínios de repetição de anquirina projetados com resíduos de superfície alterados
BR112021024237A2 (pt) Domínio de repetição de anquirina projetado com estabilidade aprimorada
CO2020010303A2 (es) Conjugados de il-15, y sus usos
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
BR112022022942A2 (pt) Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada
BRPI0616824B8 (pt) peptídeo quimérico, seu uso, composição farmacêutica compreendendo o mesmo, e kit
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
CO2022017445A2 (es) Proteínas multiespecíficas
AR103714A1 (es) Proteínas específicas para pioverdina y pioquelina
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
PH12022552935A1 (en) Stabilized coronavirus spike protein fusion proteins
CL2023000477A1 (es) Proteínas de unión restringidas activadas de forma condicional
BR112022018491A2 (pt) Marcadores de superfície celular recombinante
UY40153A (es) Anticuerpos
MX2024010178A (es) Anticuerpos capaces de unirse a la proteina de la espicula de coronavirus sars-cov-2
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2020009507A (es) Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos.
BR112021018124A2 (pt) Linhagem celular compreendendo marcador de seleção e usos do mesmo para produção de proteína
BR112019005959A2 (pt) gene dgkk recombinante para terapia genética da síndrome do x frágil
MX2022003507A (es) Modulos de union que comprenden dominios ehd2 modificados.
AR122100A1 (es) Proteínas multiespecíficas
AR117019A1 (es) Conjugados de interleuquina 10 y usos de los mismos